Myasthenia gravis is a neuromuscular disease characterised by weakness and abnormal fatigability of skeletal muscle based on failure of neuromuscular transmission. The cause of the transmission failure has long been thought to lie in the presynaptic nerve terminal of the neuromuscular junction (Elmqvist et al., 1964) . Recently, however, a large body of evidence has accumulated pointing to the postsynaptic membrane as the site of the defect. The findings indicate a reduced number of receptors available for bungarotoxin binding at the endplate region (Fambrough et al., 1973; Engel et al., 1977a) . It has been shown that the reduced sensitivity of myasthenic muscle endplates to microiontophoretically applied acetylcholine , as well as the decreased bungarotoxin binding, can be accounted for by either loss or damage of receptors, or their occlusion by some other agent to which they will bind (Engel et al., 1977a, b) . Structural alterations of the postsynaptic muscle membrane (Engel and Santa, 1971 ) may also interfere with transmitter diffusion to the receptor or with the receptor itself.
Several lines of evidence now suggest that the reduction in receptor availability involves a Presented in part at the Eleventh World Congress of Neurology, Amsterdam, 1977. humorally mediated autoimmune reaction against the ACh-R:
1. Immunisation of animals including primates with purified ACh-R results in a myasthenialike disease (experimental autoimmune myasthenia gravis) (Patrick and Lindstrom, 1973; Green et al., 1975; Granato et al., 1976; Sanders et al., 1976) . 2. Antibodies against ACh-R were demonstrated in the serum of patients with myasthenia gravis in vitro (Almon et al., 1974; Aharonov et al., 1975; Bender et al., 1975; Lindstrom et al., 1976a; Mittag et al., 1976) using various techniques. 3. Passive transfer of immunoglobulin G from patients with myasthenia gravis to mice reproduces typical features of the disease (mouse passive transfer model) (Toyka et al., 1975 (Toyka et al., , 1977 . 4. Incubation of cultured fetal muscle cells with myasthenic immunoglobulins results in an accelerated degradation of ACh-R Kao and Drachman, 1977) , and to a reduction in acetylcholine sensitivity in vitro Bevan et al., 1977) . 5. Immunoglobulin-like particles , and more recently IgG and C3 (Engel et al., 1977b) , have been located by electronmicroscopical examination at the endplate membrane in human myasthenic muscle. (Toyka et al., 1975 (Toyka et al., , 1977 (Diem and Lentner, 1968 . In 11 of 13 tested patients transfer of the immunoglobulin fraction caused a lowering of the average miniature endplate potential below the lowest control value (0.50 mV) ( Table 1 ). In two experiments we found an average MEPP amplitude of 0.53 mV, which was in the lower ran,e of the control values. In the present series all of eight sera from male patients and three of five females gave a positive result. Two mice injected with the serum of one patient (number 6) showed mild clinical signs of muscle weakness with dragging gait and reduced strength of the forelimbs when holding on to the grid of the cage. Neither the remaining myasthenic sera nor any of the control sera caused similar signs in any animal.
We Electronmicroscopical examination of serial and random sections of the endplates of two markedly affected diaphragms after treatment with myasthenic immunoglobulins revealed essentially normal nerve and muscle junctional components (Fig. 3) . In a number of endplates some regions of the postsynaptic membrane showed electron-dense material the density of which approximates that of the inner part of the basal membrane. It appeared as a series of five to 10 variably shaped spikelets located at the tips of the synaptic folds measuring 50-150 A in length and up to 50 A in width and abutting on the outer surface of the postsynaptic membrane (Fig. 3, inset) . In a few control endplates similar material was also observed.
Discussion
In confirmation of previous reports it was shown in the present series of experiments that transfer of the immunoglobulin fraction of sera from myasthenic patients to mice produces electrophysiological and, in some animals, clinical signs similar to those found in the human disorder.
The average endplate potential amplitude in animals treated with Ig was reduced by 33%, the average miniature endplate potential amplitude by 48%. The quantum content of each EPP was, therefore, not significantly changed compared to healthy animals (Table 2) . Miniature endplate potential frequency-another indicator of presynaptic function (Hubbard et al., 1969) -was not grossly changed in myasthenic animals.
Similar results have been obtained in human myasthenia gravis (Elmqvist et at., 1964; Albuquerque et al., 1976; Rash et al., 1976) and in the chronic phase of experimental autoimmune myasthenia gravis in rats (Lambert et al., 1976) . adding support to the concept of a postsynaptic defect in myasthenia gravis, which had earlier been proposed on the basis of a decreased number of bungarotoxin binding sites (Fambrough et al., 1973) . Except for ACh sensitivity which was not measured by us in these experiments, all parameters of the MPTM are in good agreement with those reported for human myasthenia gravis and chronic experimental autoimmune myasthenia gravis. Unless heterogeneous and homogeneous immunoglobulins have different actions at the neuromuscular junction we think it likely that a postsynaptic effect explains our findings.
By contrast, in the acute phase of experimental autoimmune myasthenia gravis (Lambert et al., 1976) , or after passive transfer of serum from rats with the chronic form of this disease to normal recipient animals (Lindstrom et al., 1976a) , the quantum content of EPPs and MEPP frequency are greatly reduced thus adding a presynaptic component to the transmission failure in these animals.
In humans with myasthenia gravis no equivalent phenomenon has yet been observed.
We find that serum from male and female patients was equally active on mouse preparations, and we, therefore, do not favour the hypothesis that the pathogenetic mechanism is basically different in male and female myasthenic patients (Feltkamp et al., 1974; Pirskanen, 1976 The bioassay appears to be specific for myasthenia gravis as judged by the individual disease controls in this study.
The in vitro assay of binding antibodies against ACh-R extracted with detergent from human or mammalian muscle has been reported to be slightly more sensitive than the in vivo mouse response and highly specific for myasthenia gravis (Lindstrom et al., 1976b) . However, tests measuring antibodies which block bungarotoxin binding to ACh-R are much less sensitive (Almon et al., 1974; Lindstrom et al., 1976b; Mittag et al., 1976) . The variation in the sensitivity may in part be due to the difference in the physicochemical properties of the ACh-R after being disrupted from the junctional membrane with detergent (Changeux et al., 1976; Lennon, 1976 ).
Other differences in the model system response may indicate variations in the cross-reactivity between myasthenic Ig and receptors from different mammalian species (mouse versus rat versus human muscle). The fact that human "myasthenogenic" immunoglobulins act across a species barrier demonstrates that both human and mouse ACh-R share a sufficient number of antigenbinding sites at or close to the ACh-binding site to allow for a decrease in the response to the transmitter.
Preliminary evidence from a limited number of endplates from clearly affected diaphragms after passive transfer of myasthenic immunoglobulins indicates that no gross abnormality can be demonstrated. The endplates in these muscles do not look like those from patients with chronic myasthenia gravis (Engel and Santa, 1971) or from rats with chronic experimental autoimmune myasthenia gravis (Engel et al., 1976) under the electronmicroscope. They resemble rather the ultrastructural findings described in patients with myasthenia gravis of recent onset Engel et al., 1977a) where the authors found virtually normal junctional components despite markedly decreased MEPP amplitudes. The linear densities we have observed in some endplates of the affected diaphragms but, on occasion, also in control endplates, seem to be nonspecific. Similarly shaped material has been demonstrated in rabbits with experimental autoimmune myasthenia gravis and in control animals (Thornell et al., 1976 Appel et al., 1977; Bevan et al., 1977; Kao and Drachman, 1977) . This does not necessarily imply a similar mechanism in junctional ACh-R of intact endplates.
The fact that the mouse passive transfer model combines a marked neurophysiological defect with lack of gross structural alterations makes it a suitable tool for studies on the myasthenic transmission failure.
